154 related articles for article (PubMed ID: 38112161)
1. Alemtuzumab-induced immune-mediated thrombotic thrombocytopenic purpura: A newly described drug-related autoimmune disease.
Bourdin V; Fossé Q; Lambotte O; Joly B; Coppo P; Anguel N; Labeyrie C
Br J Haematol; 2024 Apr; 204(4):1459-1463. PubMed ID: 38112161
[TBL] [Abstract][Full Text] [Related]
2. The standard of care for immune thrombotic thrombocytopenic purpura today.
Zheng XL
J Thromb Haemost; 2021 Aug; 19(8):1864-1871. PubMed ID: 34060225
[TBL] [Abstract][Full Text] [Related]
3. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP).
Shah N; Rutherford C; Matevosyan K; Shen YM; Sarode R
Br J Haematol; 2013 Nov; 163(4):514-9. PubMed ID: 24111495
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 2023.
Matsumoto M; Miyakawa Y; Kokame K; Ueda Y; Wada H; Higasa S; Yagi H; Ogawa Y; Sakai K; Miyata T; Morishita E; Fujimura Y;
Int J Hematol; 2023 Nov; 118(5):529-546. PubMed ID: 37689812
[TBL] [Abstract][Full Text] [Related]
5. Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura.
Pascual-Izquierdo C; Del Rio-Garma J; de la Rubia J; Viejo A; Mingot E; Cid J; Solanich X; Fernández-Sojo J; Martín-Sánchez J; Hernández L; García-Gala JM; Alonso N; González V; Oliva A; Gómez-Seguí I; Goterris R; Guerra L; García-Candel F; Fernández-Docampo M; Antelo ML; Salgado-Barreira Á; Salinas R;
J Clin Apher; 2021 Aug; 36(4):563-573. PubMed ID: 33780553
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies: Lessons learned from a 14-year retrospective study.
Tau J; Fernando LP; Munoz MC; Poh C; Krishnan VV; Dwyre DM
Ther Apher Dial; 2023 Feb; 27(1):136-145. PubMed ID: 35501999
[TBL] [Abstract][Full Text] [Related]
7. Best practices and recommendations for drug regimens and plasma exchange for immune thrombotic thrombocytopenic purpura.
Gómez-Seguí I; Pascual Izquierdo C; de la Rubia Comos J
Expert Rev Hematol; 2021 Aug; 14(8):707-719. PubMed ID: 34275393
[TBL] [Abstract][Full Text] [Related]
8. Autoantibodies enhance ADAMTS-13 clearance in patients with immune thrombotic thrombocytopenic purpura.
Underwood MI; Alwan F; Thomas MR; Scully MA; Crawley JTB
J Thromb Haemost; 2023 Jun; 21(6):1544-1552. PubMed ID: 36813118
[TBL] [Abstract][Full Text] [Related]
9. Current insight into thrombotic thrombocytopenic purpura.
Verbeke L; Delforge M; Dierickx D
Blood Coagul Fibrinolysis; 2010 Jan; 21(1):3-10. PubMed ID: 19851089
[TBL] [Abstract][Full Text] [Related]
10. [Thrombotic thrombocytopenic purpura].
Yoshitaka M
Rinsho Ketsueki; 2021; 62(5):430-434. PubMed ID: 34108326
[TBL] [Abstract][Full Text] [Related]
11. Presentation of concurrent thrombotic thrombocytopenic purpura and Graves' disease.
Casasanta NA; Shah N; Troy K; Edwards C; Patel RB
Blood Coagul Fibrinolysis; 2022 Oct; 33(7):422-424. PubMed ID: 35867945
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in a child with autoimmune thrombotic thrombocytopenic purpura refractory to plasma exchange.
Narayanan P; Jayaraman A; Rustagi RS; Mahadevan S; Parameswaran S
Int J Hematol; 2012 Jul; 96(1):122-4. PubMed ID: 22552883
[TBL] [Abstract][Full Text] [Related]
13. Thrombotic thrombocytopenic purpura.
Joly BS; Coppo P; Veyradier A
Blood; 2017 May; 129(21):2836-2846. PubMed ID: 28416507
[TBL] [Abstract][Full Text] [Related]
14. Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab?
Picod A; Veyradier A; Coppo P
J Thromb Haemost; 2021 Jan; 19(1):58-67. PubMed ID: 33236389
[TBL] [Abstract][Full Text] [Related]
15. Management of immune thrombotic thrombocytopenic purpura with caplacizumab: a Canadian, single-centre, real-world experience.
Tse B; Buchholz M; Pavenski K
Platelets; 2023 Dec; 34(1):2157807. PubMed ID: 36636834
[TBL] [Abstract][Full Text] [Related]
16. Plasma Cell Directed Therapy for Immune Thrombotic Thrombocytopenic Purpura (iTTP).
Chen M; Shortt J
Transfus Med Rev; 2022 Oct; 36(4):204-214. PubMed ID: 36396570
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab-induced thrombotic thrombocytopenic purpura.
Dickey MS; Raina AJ; Gilbar PJ; Wisniowski BL; Collins JT; Karki B; Nguyen AD
J Oncol Pharm Pract; 2020 Jul; 26(5):1237-1240. PubMed ID: 31718453
[TBL] [Abstract][Full Text] [Related]
18. [Venous thrombo-embolism during immune-mediated thrombotic thrombocytopenic purpura is prevalent in patients with a prolonged treatment with therapeutic plasma exchange].
Benhamou Y; Sauvètre G; Grangé S; Veyradier A; Coppo P
Rev Med Interne; 2020 Dec; 41(12):809-813. PubMed ID: 32727695
[TBL] [Abstract][Full Text] [Related]
19. [Frontline clinical practice for thrombotic thrombocytopenic purpura].
Miyakawa Y
Rinsho Ketsueki; 2020; 61(9):1331-1337. PubMed ID: 33162533
[TBL] [Abstract][Full Text] [Related]
20. COVID-19 as a Potential Trigger for Immune Thrombotic Thrombocytopenic Purpura and Reason for an Unusual Treatment: A Case Report.
Schwaegermann MK; Hobohm L; Rausch J; Reuter M; Griemert TF; Sivanathan V; Falter T; Sprinzl MF; Lackner KJ; Galle PR; Konstantinides S; Theobald M; von Auer C
Hamostaseologie; 2023 Jun; 43(3):215-218. PubMed ID: 34327693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
